Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The study's purpose is to understand the effects of a new treatment (suba-itraconazole and
tamoxifen) in epithelial ovarian cancer.
Who is it for? Patients may be eligible to join this study with ovarian cancer resistant to
platinum-based chemotherapy agents
Study Details:
Participants will receive different doses of tamoxifen and suba-itraconazole to determine the
optimal combination dose.
Participants will be seen by the investigators once a week for the first 3 weeks and then
once every 4 weeks. Participant will be reviewed by a clinician and undergo regular blood
tests, cardiac monitoring and imaging assessments.
Phase:
Phase 1
Details
Lead Sponsor:
Anthony Joshua, FRACP
Collaborators:
Concord Hospital Prince of Wales Hospital, Sydney Royal Prince Alfred Hospital, Sydney, Australia St Vincent's Hospital, Sydney